EGFR exon 20 mutation
|
Solid Tumor
|
EGFR exon 20 mutation
|
Solid Tumor
|
tarloxotinib bromide Sensitive: C2 – Inclusion Criteria
|
tarloxotinib bromide Sensitive: C2 – Inclusion Criteria
|
EGFR exon 20 mutation
|
NSCLC
|
EGFR exon 20 mutation
|
NSCLC
|
furmonertinib Sensitive: C2 – Inclusion Criteria
|
furmonertinib Sensitive: C2 – Inclusion Criteria
|
EGFR exon 20 mutation
|
NSCLC
|
EGFR exon 20 mutation
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
EGFR exon 20 mutation
|
NSCLC
|
EGFR exon 20 mutation
|
NSCLC
|
erlotinib Sensitive: C3 – Early Trials
|
erlotinib Sensitive: C3 – Early Trials
|
EGFR exon 20 mutation
|
NSCLC
|
EGFR exon 20 mutation
|
NSCLC
|
icotinib Sensitive: C3 – Early Trials
|
icotinib Sensitive: C3 – Early Trials
|
EGFR exon 20 mutation
|
NSCLC
|
EGFR exon 20 mutation
|
NSCLC
|
afatinib Sensitive: C3 – Early Trials
|
afatinib Sensitive: C3 – Early Trials
|
EGFR exon 20 mutation
|
NSCLC
|
EGFR exon 20 mutation
|
NSCLC
|
FCN-411 Sensitive: C3 – Early Trials
|
FCN-411 Sensitive: C3 – Early Trials
|